Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

SAVITRI KRISHNAMURTHY

Allopathic & Osteopathic Physicians Pathology Anatomic Pathology & Clinical Pathology

NPI
1194772988
CMS profile
397083
Location
HOUSTON, TX

General Payments · PY2019–2024

$63,810.35

  • Reported across 55 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$16,938.82

14 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $14,216.32 13
Roche Diagnostics Corporation $2,722.50 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,008.80 5
PY2020 $3,050.00 1
PY2021 $8,798.75 6
PY2022 $17,091.25 13
PY2023 $13,922.73 16
PY2024 $16,938.82 14

Payment records · PY2024 (14)

Sorted by paying entity, then date · as published by CMS

Program year 2024 20192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $1,815.00 01/04/2024 Consulting Fee Undisputed 01/23/2026 1105228967 CMS
AstraZeneca Pharmaceuticals LP $655.66 01/08/2024 Travel and Lodging Undisputed 01/23/2026 1104210569 CMS
AstraZeneca Pharmaceuticals LP $796.14 01/08/2024 Travel and Lodging Undisputed 01/23/2026 1105719896 CMS
AstraZeneca Pharmaceuticals LP $59.52 01/08/2024 Food and Beverage Undisputed 01/23/2026 1105871803 CMS
AstraZeneca Pharmaceuticals LP $907.50 02/10/2024 Consulting Fee Undisputed 01/23/2026 1105636750 CMS
AstraZeneca Pharmaceuticals LP $907.50 02/13/2024 Consulting Fee Undisputed 01/23/2026 1105291252 CMS
AstraZeneca Pharmaceuticals LP $1,512.50 04/28/2024 Consulting Fee Undisputed 01/23/2026 1105770510 CMS
AstraZeneca Pharmaceuticals LP $1,210.00 05/13/2024 Consulting Fee Undisputed 01/23/2026 1105258695 CMS
AstraZeneca Pharmaceuticals LP $1,512.50 05/14/2024 Consulting Fee Undisputed 01/23/2026 1105265151 CMS
AstraZeneca Pharmaceuticals LP $907.50 06/10/2024 Consulting Fee Undisputed 01/23/2026 1104508926 CMS
AstraZeneca Pharmaceuticals LP $907.50 07/05/2024 Consulting Fee Undisputed 01/23/2026 1105589398 CMS
AstraZeneca Pharmaceuticals LP $2,117.50 11/06/2024 Consulting Fee Undisputed 01/23/2026 1104548000 CMS
AstraZeneca Pharmaceuticals LP $907.50 11/07/2024 Consulting Fee Undisputed 01/23/2026 1105797848 CMS
Roche Diagnostics Corporation $2,722.50 10/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1089610272 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.